Apellis Pharmaceuticals Statistics
Share Statistics
Apellis Pharmaceuticals has 124.39M shares outstanding. The number of shares has increased by 3.16% in one year.
| Shares Outstanding | 124.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 101.56M |
| Failed to Deliver (FTD) Shares | 33.02K |
| FTD / Avg. Volume | 1.05% |
Short Selling Information
The latest short interest is 20.01M, so 16.09% of the outstanding shares have been sold short.
| Short Interest | 20.01M |
| Short % of Shares Out | 16.09% |
| Short % of Float | 19.72% |
| Short Ratio (days to cover) | 5.22 |
Valuation Ratios
The PE ratio is -13.44 and the forward PE ratio is -34.83.
| PE Ratio | -13.44 |
| Forward PE | -34.83 |
| PS Ratio | 17.91 |
| Forward PS | 3.2 |
| PB Ratio | 36.52 |
| P/FCF Ratio | -11.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Apellis Pharmaceuticals Inc. has an Enterprise Value (EV) of 6.86B.
| EV / Earnings | -12.98 |
| EV / Sales | 17.3 |
| EV / EBITDA | -13.86 |
| EV / EBIT | -13.27 |
| EV / FCF | -11.52 |
Financial Position
The company has a current ratio of 3.1, with a Debt / Equity ratio of 0.48.
| Current Ratio | 3.1 |
| Quick Ratio | 2.5 |
| Debt / Equity | 0.48 |
| Total Debt / Capitalization | 32.35 |
| Cash Flow / Debt | -6.39 |
| Interest Coverage | -17.48 |
Financial Efficiency
Return on equity (ROE) is -2.72% and return on capital (ROIC) is -169.98%.
| Return on Equity (ROE) | -2.72% |
| Return on Assets (ROA) | -0.67% |
| Return on Capital (ROIC) | -169.98% |
| Revenue Per Employee | 564.94K |
| Profits Per Employee | -753.03K |
| Employee Count | 702 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 0.4 |
Taxes
| Income Tax | 2.13M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -58.24% in the last 52 weeks. The beta is 0.87, so Apellis Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | -58.24% |
| 50-Day Moving Average | 31.44 |
| 200-Day Moving Average | 37.3 |
| Relative Strength Index (RSI) | 34.11 |
| Average Volume (20 Days) | 3.14M |
Income Statement
In the last 12 months, Apellis Pharmaceuticals had revenue of 396.59M and earned -528.63M in profits. Earnings per share was -4.45.
| Revenue | 396.59M |
| Gross Profit | 338.08M |
| Operating Income | -517.12M |
| Net Income | -528.63M |
| EBITDA | -495.21M |
| EBIT | -517.12M |
| Earnings Per Share (EPS) | -4.45 |
Balance Sheet
The company has 351.19M in cash and 110.93M in debt, giving a net cash position of 240.26M.
| Cash & Cash Equivalents | 351.19M |
| Total Debt | 110.93M |
| Net Cash | 240.26M |
| Retained Earnings | -2.84B |
| Total Assets | 901.87M |
| Working Capital | 642.64M |
Cash Flow
In the last 12 months, operating cash flow was -594.74M and capital expenditures -773.00K, giving a free cash flow of -595.51M.
| Operating Cash Flow | -594.74M |
| Capital Expenditures | -773.00K |
| Free Cash Flow | -595.51M |
| FCF Per Share | -5.02 |
Margins
Gross margin is 85.25%, with operating and profit margins of -130.39% and -133.29%.
| Gross Margin | 85.25% |
| Operating Margin | -130.39% |
| Pretax Margin | -132.76% |
| Profit Margin | -133.29% |
| EBITDA Margin | -124.87% |
| EBIT Margin | -130.39% |
| FCF Margin | -150.16% |
Dividends & Yields
APLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.07% |
| FCF Yield | -17.29% |
Analyst Forecast
The average price target for APLS is $41, which is 48.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $41 |
| Price Target Difference | 48.1% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | 0.08 |
| Piotroski F-Score | 4 |